| Literature DB >> 27322241 |
Ailton Cesar Lemes1, Luisa Sala2, Joana da Costa Ores3, Anna Rafaela Cavalcante Braga4, Mariana Buranelo Egea5, Kátia Flávia Fernandes6.
Abstract
Bioactive peptides are considered the new generation of biologically active regulators that not only prevent the mechanism of oxidation and microbial degradation in foods but also enhanced the treatment of various diseases and disorders, thus increasing quality of life. This review article emphasizes recent advances in bioactive peptide technology, such as: (i) new strategies for transforming bioactive peptides from residual waste into added-value products; (ii) nanotechnology for the encapsulation, protection and release of controlled peptides; and (iii) use of techniques of large-scale recovery and purification of peptides aiming at future applications to pharmaceutical and food industries.Entities:
Keywords: bioactivity; nanotechnology; peptides; purification; residual waste
Mesh:
Substances:
Year: 2016 PMID: 27322241 PMCID: PMC4926483 DOI: 10.3390/ijms17060950
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1An ideal process should avoid generation of waste. Adapted from Pelizer, Pontieri and Moraes [68].
Protein content of agro-industrial waste available to obtain bioactive peptides.
| Agro-Industrial Waste | Proteins (%) | Reference |
|---|---|---|
| Alga protein | >50.0 | [ |
| By-products of shrimp ( | >64.0 | [ |
| Chicken raw feathers | 85.3 | [ |
| Fish and shellfish | 10–23 | [ |
| Olive stone | >22.0 | [ |
| >27.0 | [ | |
| Sheep raw wool | 80.7 | [ |
| Soybean meal | 90–93 | [ |
Peptides from agro-industrial waste by enzymatic hydrolyses with their respective bioactivity and purification techniques.
| Agro-Industrial Waste | Bioactivity | Hydrolysis | Techniques Purification | Reference |
|---|---|---|---|---|
| ACE | Acid protease (fungal protease concentrate) + Flavourzyme | Gel filtration chromatography | [ | |
| Antioxidant and anticancer activities | Pepsin | Ammonium sulfate precipitation, gel filtration, ion exchange chromatography | [ | |
| Chicken feathers | Antioxidant, ACE- and DPPH-IV inhibitory activities | Ultrafiltration, HPLC | [ | |
| Chicken feathers | Antioxidant activity | [ | ||
| Sheep wool | Antioxidant activity | [ | ||
| Heads and viscera of sardinelle | ACE-inhibitory activity | Crude enzyme extract from sardine ( | Gel filtration | [ |
| ACE-inhibitory activity | Extracellular proteases from | Ultrafiltration | [ | |
| Tuna dark muscle | Antioxidant activity | Orientase and protease XXIII | Gel filtration, two-steps of HPLC | [ |
| Residual meat of hard clam | ACE-inhibitory activity | Protamex | Gel filtration | [ |
| Chum salmon ( | ACE-inhibitory activity | Trypsin | Gel filtration, reversed-phase HPLC | [ |
| Atlantic rock crab ( | Antibacterial activity | Protamex | Micro-, ultra- and nanofiltration, ion exchange chromatography | [ |
| Egg-yolk phospholipid extraction | ACE-inhibitory activity | Protease from | Ultrafiltration, gel filtration and reversed-phase HPLC | [ |
HPLC: high-performance liquid chromatography.
Principles of the chromatography methods used for bioactive peptide purification.
| Method | Principle |
|---|---|
| Reversed-phase | Based on hydrophobicity. Consists of a stationary phase of lower polarity and a mobile phase of higher polarity. |
| Ion exchange | The distribution and surface charge of the peptide determines the interaction of charged groups with the surface of the stationary phase. |
| Size exclusion | Based on separation process according to the size of the peptide relative to pore sizes in the stationary phase. Used primarily in the early stages of purification of the peptide, when performed in multiple steps. |
| Affinity | Based on the biological specificity of the peptide. Consists of a ligand (small specific biomolecule such as an antibody) that is immobilized in the column. The separation occurs because of highly specific biochemical interactions between the peptide and the ligand. |
Reference: Adapted from Espitia et al. [109].
Brief general descriptions of membrane processes.
| Method | Description |
|---|---|
| Ultrafiltration (UF) | UF involves the use of membranes with a molecular weight cutoff in the range of 1–200 kDa and a pore size of approximately 0.01 μm; it is performed at <1000 kPa. |
| Microfiltration (MF) | MF is a pressure-driven membrane process that involves the use of membranes with pore size of 0.2–2 μm; it can selectively separate particles with molecular weights >200 kDa. |
| Reverse osmosis (RO) | RO membranes are characterized by a molecular weight cutoff of approximately 100 Da; the process involves pressures 5–10 times higher than those used in UF. |
| Nanofiltration (NF) | NF separates particles with molecular weights in the range of 300–1000 Da. It allows the rejection of ions based on their diffusion characteristics and charge. NF is capable of removing ions that contribute significantly to the osmotic pressure, thus allowing operation pressures lower than those needed in RO. |
Reference: Adapted from Rosenberg [122].
Figure 2Diagrammatic representation of the size range of material in nanotechnology.
Application of bioactive peptides using nanotechnology.
| Application | Description | Reference |
|---|---|---|
| Biodegradable wound dressing nonofiber | Fabrication of nanofibrous P(3HB- | [ |
| Intracellular delivery | Photosensitizer and polycationic peptide-labeled streptavidin as a nano-carrier for light-controlled protein transduction | [ |
| Drug delivery | Ionic graft copolymers to fold and activate ionic peptides through inter-polyelectrolyte nano-assembly | [ |
| Implant materials in bone graft substitutes | Peptide decorated nano-hydroxyapatite with enhanced bioactivity and osteogenic differentiation via polydopamine coating | [ |
| Brain drug delivery | Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier | [ |
| Antioxidant Activity | Bioactive peptides/chitosan nanoparticles enhance cellular antioxidant activity of (−)-epigallocatechin-3-gallate | [ |
| Cancer management | Nanochemoprevention by encapsulation of (−)-epigallocatechin-3-gallate with bioactive peptides/chitosan nanoparticles for enhancement of its bioavailability | [ |
| Drug delivery | Production of porous nano-HA/collagen/PLLA scaffold containing chitosan microspheres for controlled delivery of synthetic peptide derived from BMP-2 | [ |
| Treatment of atherosclerosis | [ | |
| Cell therapies | Self-assembly combining two bioactive peptide-amphiphile molecules into nanofibers by electrostatic attraction | [ |